Open AccessEfficient Anti-Glioma Therapy Through the Brain-Targeted RVG15-Modified Liposomes Loading Paclitaxel-Cholesterol Complex
Author(s) -
Xin Xin,
Wei Liu,
Zheao Zhang,
Ying Han,
Qi Li,
Yingying Zhang,
Xintong Zhang,
Hongxia Duan,
Liqing Chen,
Mingji Jin,
Qiming Wang,
Zhong-Gao Gao,
Wei Huang
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s318266
Subject(s) - paclitaxel , glioma , in vivo , liposome , pharmacology , blood–brain barrier , drug delivery , in vitro , brain tumor , cancer research , medicine , chemistry , chemotherapy , materials science , biology , biochemistry , nanotechnology , pathology , central nervous system , microbiology and biotechnology
Glioma is the most common primary malignant brain tumor with a dreadful overall survival and high mortality. One of the most difficult challenges in clinical treatment is that most drugs hardly pass through the blood-brain barrier (BBB) and achieve efficient accumulation at tumor sites. Thus, to circumvent this hurdle, developing an effectively traversing BBB drug delivery nanovehicle is of significant clinical importance. Rabies virus glycoprotein (RVG) is a derivative peptide that can specifically bind to nicotinic acetylcholine receptor (nAChR) widely overexpressed on BBB and glioma cells for the invasion of rabies virus into the brain. Inspired by this, RVG has been demonstrated to potentiate drugs across the BBB, promote the permeability, and further enhance drug tumor-specific selectivity and penetration.